DexCom $1.05 billion convertible notes offering
Davis Polk advised the representatives of several initial purchasers in connection with a Rule 144A offering by DexCom, Inc. of $1.05 billion aggregate principal amount of its 0.250%…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
NanoString Technologies $230 million convertible senior notes offering
Davis Polk advised the initial purchasers in connection with a Rule 144A offering by NanoString Technologies, Inc. of $230 million aggregate principal amount of its 2.625% convertible…
Atara Biotherapeutics $100 million at-the-market offering
Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Atara Biotherapeutics, Inc. of its common stock for up to an aggregate amount of $100 million.
Based in…
Revance Therapeutics $287.5 million convertible senior notes offering
Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Revance Therapeutics, Inc. of $287.5 million aggregate principal amount of its 1.75% convertible senior…
Revance Therapeutics, Inc. $110 Million Common Stock Offering
Davis Polk advised the joint lead book-running managers and representatives of the several underwriters in connection with a $110.5 million SEC-registered common stock offering by…
BioNTech SE Initial Public Offering on Nasdaq
Davis Polk advised the underwriters in connection with the $150 million initial public offering of 10,000,000 American Depositary Shares of BioNTech SE. In addition, the underwriters have…
Aprea Therapeutics, Inc. Initial Public Offering
Davis Polk advised the underwriters in connection with the $97.75 million initial public offering of 6,516,667 shares of common stock of Aprea Therapeutics, Inc., which includes 850,000…
PTC Therapeutics, Inc. Concurrent $100 Million Common Stock Offering and $287.5 Million Convertible Senior Notes Offering
Davis Polk advised the underwriter in connection with the SEC-registered offering by PTC Therapeutics, Inc. of 2,475,248 shares of its common stock and the initial purchaser in a concurrent…
TPG Capital acquisition of Convey Health Solutions and related financing
Davis Polk advised TPG Capital, the private equity platform of global alternative asset firm TPG, on its acquisition of Convey Health Solutions from New Mountain Capital and related…
$1.075 billion financing for Option Care's combination with BioScrip
Davis Polk advised the administrative agent, joint lead arranger and joint bookrunner in connection with a $925 million first-lien term loan facility and a $150 million asset-based…